Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Quick Takes The use of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (AF) weighing ≥120 kg was not associated with an increased risk of thromboembolic events or bleeding compared to those patients weighing 60-120 kg. The results of this study add to the growing body of literature demonstrating that DOACs are a...

  • This was a single-center retrospective study in patients weighing ≥120 kg with nonvalvular AF who were taking apixaban, rivaroxaban, or dabigatran between January 1, 2011 and September 30, 2018. A total of 348 patients >18 years of age were included and were matched to patients weighing 60-120 kg based on age, sex, ethnicity, and prescribed oral anticoagulant. #rivaroxaban